Calan has the active ingredient verapamil. It is also known by other names such as Isoptin and Verelan. This medication is used to treat high blood pressure, chest pain (angina), and certain heart rhythm disorders.
The price scale for Calan typically fluctuates between £0.27 and £1 per pills. Factors such as packaging dimensions and active ingredient ratio (30 or 360 mg) come into play.
Calan contains the active ingredient Verapamil Hydrochloride, a calcium channel blocker. It works by relaxing the muscles of the heart and blood vessels. This medicine affects the movement of calcium into the cells of the heart and blood vessels, preventing them from constricting too tightly.
Calan is classified under several therapeutic categories: antiarrhythmics, antihypertensives, and antianginals. As a multi-use medication, it provides treatment for various cardiovascular ailments.
Calan is prescribed for managing high blood pressure (hypertension), reducing angina (chest pain), and treating specific heart rhythm disorders such as atrial fibrillation and paroxysmal supraventricular tachycardia.
Calan is available in multiple dosage forms, including extended-release tablets and immediate-release tablets. Extended-release forms are designed for once-daily dosing, while immediate-release tablets may be administered multiple times a day.
Calan should be taken orally with or without food. For optimal absorption, extended-release tablets should not be chewed or crushed. Immediate-release tablets can be split if a smaller dose is prescribed.
The dosage of Calan varies by condition and severity. For hypertension, the common starting dose is 80 mg taken three times daily. Doses for treating angina typically range from 120 mg to 480 mg per day. Adjustments should be made based on the patient’s response.
The safety and efficacy of Calan in pediatric patients have not been established. Prescription for children should be handled by a specialist, adhering to a strict benefit-risk assessment.
Calan must be administered cautiously in elderly patients due to an increased risk of adverse effects. Dose initiation typically starts at the lower end of the dosing range to account for potential kidney function impairment and increased drug sensitivity.
Renal function must be closely monitored in patients taking Calan. Adjustments to the dosage schedule might be necessary to avoid drug accumulation and potential toxicity.
Verapamil is extensively metabolized in the liver. Patients with liver function impairment may require dose adjustments. Monitoring liver enzymes is recommended to detect potential drug-induced hepatotoxicity early.
Calan interacts with several drug categories, notably beta-blockers, digitalis, and other antihypertensives, potentially causing additive effects. Concomitant use with CYP3A4 inhibitors or inducers may alter Calan’s metabolism, necessitating dose modifications.
Common adverse effects of Calan include dizziness, headache, constipation, and fatigue. Serious adverse reactions can include bradycardia (slow heart rate), hypotension (low blood pressure), and heart failure, typically requiring discontinuation or dose adjustment.
In the event of a Calan overdose, symptoms such as severe hypotension, bradycardia, and cardiac arrest may occur. Immediate medical intervention is critical, often involving gastric lavage, administration of intravenous fluids, and vasopressors.
Regular monitoring of blood pressure and heart rate is essential for patients on Calan therapy. Periodic liver and kidney function assessments are recommended, particularly for long-term use or in patients with pre-existing organ impairments.
Calan should not be abruptly discontinued to avoid rebound effects such as hypertension or angina. Tapering the dose gradually under physician supervision is advised to minimize withdrawal symptoms.
Pregnant and breastfeeding women should use Calan only if the potential benefit justifies the potential risk to the fetus or infant. Close monitoring and consideration of alternative treatments are advisable during these periods.
Store Calan tablets at room temperature, away from moisture and light. Keep the medication in a tightly closed container to preserve efficacy and prevent contamination.
Patients prescribed Calan should be informed about potential side effects and the importance of adherence to the prescribed regimen. They should be instructed to report any unusual symptoms or adverse effects promptly to healthcare providers.
Calan’s pharmacokinetics involve high oral bioavailability and extensive hepatic metabolism. The drug’s half-life ranges from 2.8 to 7.4 hours for immediate-release forms, with extended-release forms providing prolonged therapeutic effects.